SAB Biotherapeutics (SABS) Income Statement: Revenue & Earnings

SAB Biotherapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

SAB Biotherapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	1.32	2.24	23.90	60.88	55.24
Cost of Revenue	30.25	16.52	36.44	57.18	27.91
Gross Profit	-28.93	-14.28	-12.53	60.88	27.33
Operating Expenses
Research & Development	30.25	16.52	36.44	57.18	0.00
Selling, General & Administrative	13.98	23.80	16.38	17.09	6.77
Operating Expenses	13.98	23.80	28.92	74.27	6.77
Operating Income	-42.91	-38.08	-28.92	-13.39	20.56
Other Income/Expense
Interest Income	1.29	0.58	0.07	0.02	0.03
Interest Expense	-0.32	-0.32	0.30	-0.29	-0.47
Other Income/Expense	7.81	-4.39	10.43	3.48	0.00
Income
Income Before Tax	-34.11	-42.19	-18.72	-17.14	20.12
Income Tax Expense	0.00	-0.45	0.03	-0.11	0.00
Net Income	-34.11	-42.19	-18.74	-17.14	20.12
Net Income - Continuous Operations	-34.11	-42.19	-18.74	-17.14	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-38.12	-34.33	-15.12	-15.49	20.94
EBIT	-42.91	-38.08	-18.41	-17.14	20.56
Depreciation & Amortization	4.79	3.75	3.29	1.49	0.38
Earnings Per Share
Basic EPS	-4.00	-8.00	-4.00	-6.00	8.00
Diluted EPS	-4.00	-8.00	-4.00	-6.00	7.00
Basic Shares Outstanding	9.26	5.52	4.35	2.73	2.54
Diluted Shares Outstanding	9.26	5.52	4.35	2.73	2.70